ASND
Price
$152.43
Change
-$2.15 (-1.39%)
Updated
Feb 21 closing price
Capitalization
9.12B
87 days until earnings call
LSTA
Price
$2.55
Change
-$0.01 (-0.39%)
Updated
Feb 21 closing price
Capitalization
21.4M
4 days until earnings call
Ad is loading...

ASND vs LSTA

Header iconASND vs LSTA Comparison
Open Charts ASND vs LSTABanner chart's image
Ascendis Pharma A/S
Price$152.43
Change-$2.15 (-1.39%)
Volume$444.15K
Capitalization9.12B
Lisata Therapeutics
Price$2.55
Change-$0.01 (-0.39%)
Volume$4K
Capitalization21.4M
ASND vs LSTA Comparison Chart
Loading...
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASND vs. LSTA commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASND is a Hold and LSTA is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (ASND: $152.43 vs. LSTA: $2.55)
Brand notoriety: ASND and LSTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASND: 95% vs. LSTA: 8%
Market capitalization -- ASND: $9.12B vs. LSTA: $21.4M
ASND [@Biotechnology] is valued at $9.12B. LSTA’s [@Biotechnology] market capitalization is $21.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASND’s FA Score shows that 0 FA rating(s) are green whileLSTA’s FA Score has 1 green FA rating(s).

  • ASND’s FA Score: 0 green, 5 red.
  • LSTA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ASND and LSTA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASND’s TA Score shows that 6 TA indicator(s) are bullish while LSTA’s TA Score has 6 bullish TA indicator(s).

  • ASND’s TA Score: 6 bullish, 5 bearish.
  • LSTA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LSTA is a better buy in the short-term than ASND.

Price Growth

ASND (@Biotechnology) experienced а +5.80% price change this week, while LSTA (@Biotechnology) price change was +1.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

ASND is expected to report earnings on May 21, 2025.

LSTA is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASND($9.12B) has a higher market cap than LSTA($21.4M). ASND YTD gains are higher at: 10.721 vs. LSTA (-14.470). LSTA has higher annual earnings (EBITDA): -23.31M vs. ASND (-319.82M). ASND has more cash in the bank: 626M vs. LSTA (35.9M). LSTA has less debt than ASND: LSTA (181K) vs ASND (789M). ASND has higher revenues than LSTA: ASND (327M) vs LSTA (0).
ASNDLSTAASND / LSTA
Capitalization9.12B21.4M42,626%
EBITDA-319.82M-23.31M1,372%
Gain YTD10.721-14.470-74%
P/E RatioN/AN/A-
Revenue327M0-
Total Cash626M35.9M1,744%
Total Debt789M181K435,912%
FUNDAMENTALS RATINGS
ASND vs LSTA: Fundamental Ratings
ASND
LSTA
OUTLOOK RATING
1..100
326
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
81100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
4178
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (14) in the null industry is significantly better than the same rating for ASND (92) in the Biotechnology industry. This means that LSTA’s stock grew significantly faster than ASND’s over the last 12 months.

ASND's Profit vs Risk Rating (81) in the Biotechnology industry is in the same range as LSTA (100) in the null industry. This means that ASND’s stock grew similarly to LSTA’s over the last 12 months.

LSTA's SMR Rating (96) in the null industry is in the same range as ASND (100) in the Biotechnology industry. This means that LSTA’s stock grew similarly to ASND’s over the last 12 months.

ASND's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for LSTA (78) in the null industry. This means that ASND’s stock grew somewhat faster than LSTA’s over the last 12 months.

ASND's P/E Growth Rating (100) in the Biotechnology industry is in the same range as LSTA (100) in the null industry. This means that ASND’s stock grew similarly to LSTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASNDLSTA
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 6 days ago
71%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
74%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 5 days ago
67%
View a ticker or compare two or three
Ad is loading...
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BBDC10.780.28
+2.67%
Barings BDC
ARE95.570.05
+0.05%
Alexandria Real Estate Equities
PK12.63-0.40
-3.07%
Park Hotels & Resorts
AZUL1.82-0.06
-3.19%
Azul SA
NXTC0.72-0.03
-3.74%
NextCure

ASND and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASND has been loosely correlated with ORMP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASND
1D Price
Change %
ASND100%
-1.39%
ORMP - ASND
37%
Loosely correlated
-3.15%
NUVL - ASND
36%
Loosely correlated
-3.52%
AMRN - ASND
35%
Loosely correlated
-0.82%
AXON - ASND
34%
Loosely correlated
-5.28%
CASI - ASND
33%
Poorly correlated
-0.41%
More

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and HEPA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and HEPA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
-0.57%
HEPA - LSTA
31%
Poorly correlated
-9.20%
RAIN - LSTA
29%
Poorly correlated
-0.75%
ASND - LSTA
26%
Poorly correlated
-1.39%
MRUS - LSTA
25%
Poorly correlated
-0.55%
AMLX - LSTA
25%
Poorly correlated
-6.25%
More